

**IMPORTANT NOTICE**

The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's responsibility to phone and confirm that the documents were received in good order.

Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients.

**CONTENTS****INHOUD**

| <i>No.</i>   | <i>Page<br/>No.</i> | <i>Gazette<br/>No.</i> | <i>No.</i>   | <i>Bladsy<br/>No.</i> | <i>Koerant<br/>No.</i> |
|--|---------------------|------------------------|--|-----------------------|------------------------|
| <b>GENERAL NOTICE</b>  |                     |                        | <b>ALGEMENE KENNISGEWING</b>   |                       |                        |
| <b>Health, Department of</b>   |                     |                        | <b>Gesondheid, Departement van</b>   |                       |                        |
| <i>General Notice</i>  |                     |                        | <i>Algemene Kennisgewing</i>   |                       |                        |
| 848  |                     |                        | 848  |                       |                        |
| Medicines and Related Substances Act (101/1965): Medicines Control Council: Conditions of registration of a medicine in terms of the provisions of section 15 (7)..... | 3                   | 33525                  | Wet op Beheer van Medisyne en Verwante Stowwe (101/1965): Medisyne-beheerraad: Voorwaardes vir die registrasie van 'n medisyne in terme van die bepaling van artikel 15 (7)..... | 4                     | 33525                  |

---

## GENERAL NOTICE ALGEMENE KENNISGEWING

---

### NOTICE 848 OF 2010

#### MEDICINES CONTROL COUNCIL

#### CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965)

1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council
2. The manufacture of this medicine is subject to regular investigation and inspections by the inspectors appointed in terms of Section 26 of the Act, to assess compliance with current Good Manufacturing Practices.
3. The information in the package insert shall be updated on a regular basis to conform to the package insert recently approved by Council.
4. The applicant must comply with all the legal requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).
5. The registration of this medicine shall be subject to review at intervals as determined by Council regarding its quality, safety and efficacy, and the registration of this medicine may be varied subject to issues Council may deem fit.
6. The first two production batches must be fully validated in terms of the detailed process validation protocol submitted at the time of application for registration, and the validation report must be submitted within a month after completion of the validation.
7. The product may be advertised to the professions only.
8. The provisional shelf-life allocated must be confirmed with stability data over the full shelf-life period on the first two production batches (well-known API) or first three production batches (NCE) in accordance with the Stability Guideline. Stability testing submitted on any pilot batches must also be completed and reported on. The stability report must be submitted within six months after completion of the stability trial. However, Council has to be informed immediately if any parameter shows a significant change or out-of-specification result during the stability trial.
9. A post-registration inspection must be conducted on the first production batch manufactured by each local manufacturer.
10. A post-registration inspection must be conducted on the first production batch of the imported product.
11. Marketing of the product may only commence following a satisfactory post-registration inspection report.
12. One sample of every batch, together with four copies of the protocol for testing of the bulk lot and filling lot, and six copies of the certificate of release issued by a competent authority in the country in which the product was manufactured, must be submitted to the Council for lot release purposes.
13. The expiry date allocated shall be modified by adding a statement that the virus strains are currently recommended for South African usage in the specific year.
14. The strains of the master seed viruses must be approved by the Department of Health for each year.

**KENNISGEWING 848 VAN 2010****MEDISYNEBEHEERRAAD****VOORWAARDES VIR DIE REGISTRASIE VAN 'N MEDISYNE IN TERME VAN DIE  
BEPALINGS VAN ARTIKEL 15(7) VAN DIE WET OP BEHEER VAN MEDISYNE EN  
VERWANTE STOWWE, 1965 (WET 101 VAN 1965)**

1. Die applikant sal verseker dat die medisyne vervaardig en beheer word ooreenkomstig huidige Goeie Vervaardigingspraktyke soos bepaal deur die Medisynebeheerraad.
2. Die vervaardiging van hierdie medisyne is onderhewig aan gereelde ondersoeke en inspeksies deur inspekteurs, aangestel ingevolge Artikel 25 van die Wet, om die nakoming van Goeie Vervaardigingspraktyke te bepaal.
3. Die inligting soos vervat in the voubiljet moet op 'n gereelde grondslag opgedateer word in ooreenstemming met 'n voubiljet wat onlangs deur die Raad goedgekeur is.
4. Die applikant moet voldoen aan alle wettlike vereistes van die Wet op Medisyne en Verwante Stowwe, 1965 (Wet 101 van 1965).
5. Die registrasie van hierdie medisyne is onderhewig aan gereelde hersiening met tussenpose soos deur die Raad bepaal, rakende kwaliteit, veiligheid en effektiwiteit, en die registrasie van hierdie medisyne kan gewysig word onderhewig aan kwessies na goedgekeurde van die Raad.
6. Die eerste twee produksielotte moet ten volle gevalideer word ooreenkomstig die breedvoerige prosesvalidasie protokol wat ingedien is ten tye van die aansoek om registrasie, en die validasieverslag moet binne die bestek van een maand na die voltooiing van die validasie ingedien word.
7. Die produk mag slegs aan die beroepe geadverteer word.
8. Die toegekende voorlopige rakleefyd moet bevestig word met stabiliteitsdata volgens die Stabiliteitsriglyn op die eerste twee produksielotte (bekende aktiewe bestanddele), of eerste drie produksielotte (nuwe chemiese entiteite), wat die volle rakleefydperiode dek. Stabiliteitstoetse wat op proeflotte ingedien is, moet ook voltooi word en die verslae ingedien word. Die stabiliteitsverslag moet binne ses maande na voltooiing van die stabiliteitsproef ingedien word. Die Raad moet egter onmiddellik in kennis gestel word indien enige parameter 'n betekenisvolle verandering of buite-spesifikasieresultaat tydens die stabiliteitsproef lewer.
9. 'n Na-registrasie-inspeksie moet op die eerste produksielot van elke plaaslike vervaardiger uitgevoer word.
10. 'n Na-registrasie-inspeksie moet op die eerste produksielot van die ingevoerde produk uitgevoer word.
11. Bemaking van die produk mag slegs 'n aanvang neem nadat 'n bevredigende na-registrasie-inspeksieverslag gedien het.
12. Een monster van elke lot moet tesame met vier kopieë van die protokolle vir die toets van die massalot en die vullot sowel as ses kopieë van die vrystellingsertifikaat wat uitgereik is deur die verantwoordelike beheerliggaam in die land waar die produk vervaardig word, ingedien word by die Raad vir lotvrystellingsdoeleindes.
13. Die vervaldatum toegeken, sal gewysig word deur 'n verklaring by te voeg dat die virusstamme tans vir Suid-Afrikaanse gebruik gedurende die gespesifiseerde jaar aanbeveel word.
14. Die stamme van die oorspronklike saadvirusse moet elke jaar deur die Departement van Gesondheid goedgekeur word.

## MRF 15

Registration number: 35/2.7/0223  
 Name of medicine: GRAND-PA PARACETAMOL TABLETS  
 Dosage form: TABLET  
 Active ingredients: EACH TABLET CONTAINS:  
 PARACETAMOL 500,0 mg  
 SODIUM BICARBONATE 630,0 mg  
 Conditions of registration: 1, 2, 3, 4, 5, 6  
 Applicant: GROUP LABORATORIES SA (PTY) LTD  
 Manufacturer: GLAXOSMITHKLINE, DUNGARVAN, IRELAND  
 GLAXOSMITHKLINE, EPPING, CAPE TOWN  
 Packer: GLAXOSMITHKLINE, DUNGARVAN, IRELAND  
 GLAXOSMITHKLINE, EPPING, CAPE TOWN  
 Laboratory: FPRC: GLAXOSMITHKLINE, DUNGARVAN, IRELAND  
 GLAXOSMITHKLINE, EPPING, CAPE TOWN  
 FPRR: GROUP LABORATORIES, EPPING, CAPE TOWN  
 Shelf-life: 24 months  
 Date of registration: 23 JULY 2010

## MRF15

Registration number: A40/16.4/0358  
 Name of medicine: STREPSILS STRAWBERRY SUGAR-FREE  
 Dosage form: LOZENGES  
 Active ingredients: EACH LOZENGE CONTAINS:  
 AMYLMETACRESOL 0,6 mg  
 DICHLOROBENZYL ALCOHOL 1,2 mg  
 Conditions of registration: 1, 2, 3, 4, 5, 6, 8  
 Applicant: RECKITT BENCKISER PHARMACEUTICALS (PTY) LTD  
 Manufacturer: BOOTS MANUFACTURING, NOTTINGHAM, UK  
 Packer: BOOTS MANUFACTURING, NOTTINGHAM, UK  
 NATUR PRODUKT PHARMA LTD, OSTROW, MAZOWIECKA, POLAND  
 PHARMACEUTICAL CONTRACTORS, ISANDO, KEMPTON PARK  
 Laboratory: FPRC: BOOTS MANUFACTURING, NOTTINGHAM, UK  
 NATUR PRODUKT PHARMA LTD, OSTROW, MAZOWIECKA, POLAND  
 PHARMACEUTICAL CONTRACTORS, ISANDO, KEMPTON PARK  
 PHARMA-Q, INDUSTRIA-WEST, JOHANNESBURG  
 FPRR: RECKITT BENCKISER PHARMACEUTICALS, ELANDSFONTEIN  
 Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

## MRF 15

Registration number: 41/20.2.8/0747  
 Name of medicine: PREZISTA  
 Dosage form: TABLET  
 Active ingredients: EACH TABLET CONTAINS:  
 DARUNAVIR ETHANOLATE EQUIVALENT TO DARUNAVIR 300,0 mg  
 Conditions of registration: 1, 2, 3, 4, 5, 6, 7, 8  
 Applicant: PHARMACARE LIMITED  
 Manufacturer: JANSSEN ORTHO LLC, GURABO, PUERTO RICO  
 Packer: JANSSEN-CILAG SpA, SAN MICHELE, LATINA, ITALY  
 PHARMACARE LTD, KORSTEN, PORT ELIZABETH  
 Laboratory: FPRC: JANSSEN-CILAG SpA, SAN MICHELE, LATINA, ITALY  
 FPRC/FPRR: PHARMACARE LTD, KORSTEN, PORT ELIZABETH  
 FPRR: PHARMACARE LTD, WOODMEAD, SANDTON  
 Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

**MRF 15**

Registration number: 41/26/0933  
 Name of medicine: GEMTAZ 1 g  
 Dosage form: INJECTION  
 Active ingredients: EACH VIAL CONTAINS:  
 GEMCITABINE  
 HYDROCHLORIDE  
 EQUIVALENT TO  
 GEMCITABINE 1,0 g

Conditions of registration: 1, 2, 3, 4, 5, 6, 7, 8  
 Applicant: PHARMAPLAN (PTY) LTD

Manufacturer: SUN PHARMACEUTICALS  
 INDUSTRIES LTD, HALOL,  
 DISTRICT PANCHMAHAL,  
 GUJARAT, INDIA

Packer: SUN PHARMACEUTICALS  
 INDUSTRIES LTD, HALOL,  
 DISTRICT PANCHMAHAL,  
 GUJARAT, INDIA

Laboratory: FPRC: SUN PHARMACEUTICALS  
 INDUSTRIES LTD, HALOL,  
 DISTRICT PANCHMAHAL,  
 GUJARAT, INDIA  
 CONSULTING CHEMICAL  
 LABORATORIES,  
 ATLASVILLE, BOKSBURG

FPRR: PHARMAPLAN, MIDRAND,  
 RSA

Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

**MRF15**

Registration number: 41/26/0934  
 Name of medicine: GEMTAZ 200 mg  
 Dosage form: INJECTION  
 Active ingredients: EACH VIAL CONTAINS:  
 GEMCITABINE  
 HYDROCHLORIDE  
 EQUIVALENT TO  
 GEMCITABINE 200,0 mg

Conditions of registration: 1, 2, 3, 4, 5, 6, 7, 8  
 Applicant: PHARMAPLAN (PTY) LTD

Manufacturer: SUN PHARMACEUTICALS  
 INDUSTRIES LTD, HALOL,  
 DISTRICT PANCHMAHAL,  
 GUJARAT, INDIA

Packer: SUN PHARMACEUTICALS  
 INDUSTRIES LTD, HALOL,  
 DISTRICT PANCHMAHAL,  
 GUJARAT, INDIA

Laboratory: FPRC: SUN PHARMACEUTICALS  
 INDUSTRIES LTD, HALOL,  
 DISTRICT PANCHMAHAL,  
 GUJARAT, INDIA  
 CONSULTING CHEMICAL  
 LABORATORIES,  
 ATLASVILLE, BOKSBURG

FPRR: PHARMAPLAN, MIDRAND,  
 RSA

Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

**MRF 15**

Registration number: 42/20.2.8/0202  
 Name of medicine: NYSIVIR ORAL SOLUTION 2 g  
 Dosage form: SOLUTION  
 Active ingredients: EACH 100,0 ml SOLUTION  
 CONTAINS:  
 DIDANOSINE 2,0 g

Conditions of registration: 1, 2, 3, 4, 5, 6, 7, 8  
 Applicant: AUROBINDO PHARMA (PTY)  
 LTD

Manufacturer: AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA

Packer: AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA

Laboratory: FPRC: AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA

FPRR: AUROBINDO PHARMA,  
 MEYERSDAL, JOHANNESBURG

Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/20.2.8/0203  |
| Name of medicine:           | NYSIVIR ORAL SOLUTION<br>4 g  |
| Dosage form:                | SOLUTION  |
| Active ingredients:         | EACH 100,0 ml CONTAINS:<br>DIDANOSINE 4,0 g   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | AUROBINDO PHARMA (PTY)<br>LTD   |
| Manufacturer:               | AUROBINDO PHARMA LTD,<br>UNIT III, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA<br>PRADESH, INDIA |
| Packer:                     | AUROBINDO PHARMA LTD,<br>UNIT III, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA<br>PRADESH, INDIA |
| Laboratory: FPRC:           | AUROBINDO PHARMA LTD,<br>UNIT III, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA<br>PRADESH, INDIA |
| FPRR:                       | AUROBINDO PHARMA,<br>MEYERSDAL,<br>JOHANNESBURG   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF15

|                             |  |
|-----------------------------|--|
| Registration number:        | 42/21.5.4/0218   |
| Name of medicine:           | SEREFLO 25/50 HFA  |
| Dosage form:                | INHALER  |
| Active ingredients:         | EACH ACTUATION<br>DELIVERS:<br>SALMETEROL XINAFOATE<br>EQUIVALENT TO<br>SALMETEROL 25,0 µg<br>FLUTICASON<br>E<br>PROPRIONATE 50,0 µg |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | CIPLA MEDPRO (PTY) LTD   |
| Manufacturer:               | CIPLA LTD, UNIT II,<br>VERNA, SALCETTE, GOA,<br>INDIA  |
| Packer:                     | CIPLA LTD, UNIT II,<br>VERNA, SALCETTE, GOA,<br>INDIA  |
| Laboratory: FPRC:           | CIPLA LTD, UNIT II,<br>VERNA, SALCETTE, GOA,<br>INDIA  |
| FPRR:                       | CIPLA MEDPRO, ROSEN<br>PARK, BELLVILLE   |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 42/21.5.4/0219   |
| Name of medicine:           | SEREFLO 25/125 HFA   |
| Dosage form:                | INHALER  |
| Active ingredients:         | EACH ACTUATION DELIVERS:<br>SALMETEROL XINAFOATE<br>EQUIVALENT TO<br>SALMETEROL 25,0 µg<br>FLUTICASON<br>E<br>PROPRIONATE 125,0 µg |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | CIPLA MEDPRO (PTY) LTD   |
| Manufacturer:               | CIPLA LTD, UNIT II, VERNA,<br>SALCETTE, GOA, INDIA   |
| Packer:                     | CIPLA LTD, UNIT II, VERNA,<br>SALCETTE, GOA, INDIA   |
| Laboratory: FPRC:           | CIPLA LTD, UNIT II, VERNA,<br>SALCETTE, GOA, INDIA   |
| FPRR:                       | CIPLA MEDPRO, ROSEN PARK,<br>BELLVILLE   |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 42/21.5.4/0220   |
| Name of medicine:           | SEREFLO 25/250 HFA   |
| Dosage form:                | INHALER  |
| Active ingredients:         | EACH ACTUATION<br>DELIVERS:<br>SALMETEROL XINAFOATE<br>EQUIVALENT TO<br>SALMETEROL 25,0 µg<br>FLUTICASONE<br>PROPIONATE 250,0 µg |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | CIPLA MEDPRO(PTY) LTD  |
| Manufacturer:               | CIPLA LTD, UNIT II, VERNA,<br>SALCETTE, GOA, INDIA   |
| Packer:                     | CIPLA LTD, UNIT II, VERNA,<br>SALCETTE, GOA, INDIA   |
| Laboratory: FPRC:           | CIPLA LTD, UNIT II, VERNA,<br>SALCETTE, GOA, INDIA   |
| FPRR:                       | CIPLA MEDPRO,<br>ROSENPARK, BELLVILLE  |
| Shelf-life:                 | 12 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF15

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/1.2/0423   |
| Name of medicine:           | EFEGEN XR 75  |
| Dosage form:                | CAPSULE   |
| Active ingredients:         | EACH CAPSULE<br>CONTAINS:<br>VENLAFAXINE<br>HYDROCHLORIDE<br>EQUIVALENT TO<br>VENLAFAXINE 75,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | RANBAXY (S.A.) (PTY) LTD  |
| Manufacturer:               | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA   |
| Packer:                     | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA   |
| Laboratory: FPRC:           | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA<br>KHULULEKANI<br>LABORATORY SERVICES,<br>COVENTRY PARK,<br>MIDRAND<br>CONSULTING CHEMICAL<br>LABORATORIES,<br>ATLASVILLE, BOKSBURG |
| FPRR:                       | RANBAXY (SA),<br>CENTURION, RSA   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/1.2/0424   |
| Name of medicine:           | EFEGEN XR 150   |
| Dosage form:                | CAPSULE   |
| Active ingredients:         | EACH CAPSULE CONTAINS:<br>VENLAFAXINE<br>HYDROCHLORIDE<br>EQUIVALENT TO<br>VENLAFAXINE 75,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | RANBAXY (S.A.) (PTY) LTD  |
| Manufacturer:               | RANBAXY LABORATORIES LTD,<br>PAONTA SAHIB, SIRMOUR,<br>HIMACHAL PRADESH, INDIA  |
| Packer:                     | RANBAXY LABORATORIES LTD,<br>PAONTA SAHIB, SIRMOUR,<br>HIMACHAL PRADESH, INDIA  |
| Laboratory: FPRC:           | RANBAXY LABORATORIES LTD,<br>PAONTA SAHIB, SIRMOUR,<br>HIMACHAL PRADESH, INDIA<br>KHULULEKANI LABORATORY<br>SERVICES, COVENTRY PARK,<br>MIDRAND<br>CONSULTING CHEMICAL<br>LABORATORIES, ATLASVILLE,<br>BOKSBURG |
| FPRR:                       | RANBAXY (SA), CENTURION,<br>RSA   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/1.2/0425   |
| Name of medicine:           | RAN VENLAFAXINE XR 75   |
| Dosage form:                | CAPSULE   |
| Active ingredients:         | EACH CAPSULE CONTAINS:<br>VENLAFAZINE<br>HYDROCHLORIDE<br>EQUIVALENT TO<br>VENLAFAXINE 75,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | RANBAXY (S.A.) (PTY) LTD  |
| Manufacturer:               | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA   |
| Packer:                     | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA   |
| Laboratory:<br>FPRC:        | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA<br>KHULULEKANI<br>LABORATORY SERVICES,<br>COVENTRY PARK,<br>MIDRAND<br>CONSULTING CHEMICAL<br>LABORATORIES,<br>ATLASVILLE, BOKSBURG |
| FPRR:                       | RANBAXY (SA),<br>CENTURION, RSA   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF15

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/1.2/0426   |
| Name of medicine:           | RAN VENLAFAXINE XR<br>150 mg  |
| Dosage form:                | CAPSULE   |
| Active ingredients:         | EACH CAPSULE<br>CONTAINS:<br>VENLAFAZINE<br>HYDROCHLORIDE<br>EQUIVALENT TO<br>VENLAFAXINE 150,0 mg  |
| Conditions of registration: | 1,2,3,4,5,6,7,8   |
| Applicant:                  | RANBAXY (S.A.) (PTY) LTD  |
| Manufacturer:               | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA   |
| Packer:                     | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA   |
| Laboratory:<br>FPRC:        | RANBAXY LABORATORIES<br>LTD, PAONTA SAHIB,<br>SIRMOUR, HIMACHAL<br>PRADESH, INDIA<br>KHULULEKANI<br>LABORATORY SERVICES,<br>COVENTRY PARK,<br>MIDRAND<br>CONSULTING CHEMICAL<br>LABORATORIES,<br>ATLASVILLE, BOKSBURG |
| FPRR:                       | RANBAXY (SA),<br>CENTURION, RSA   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/3.1/0467   |
| Name of medicine:           | AURO MELOXICAM 7,5 mg   |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>MELOXICAM 7,5 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | AUROBINDO PHARMA (PTY)<br>LTD   |
| Manufacturer:               | AUROBINDO PHARMA LTD,<br>UNIT III, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA |
| Packer:                     | AUROBINDO PHARMA LTD,<br>UNIT III, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA |
| Laboratory:<br>FPRC:        | AUROBINDO PHARMA LTD,<br>UNIT III, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA |
| FPRR:                       | AUROBINDO PHARMA,<br>MEYERSDAL, JOHANNESBURG  |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |



**MRF 15**

**Registration number:** 42/3.1/0468  
**Name of medicine:** AURO MELOXICAM 15 mg  
**Dosage form:** TABLET  
**Active ingredients:** EACH TABLET CONTAINS:  
 MELOXICAM 15.0 mg  
**Conditions of registration:** 1, 2, 3, 4, 5, 6, 7, 8  
**Applicant:** AUROBINDO PHARMA (PTY) LTD  
**Manufacturer:** AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
**Packer:** AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
**Laboratory: FPRC:** AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
**FPRR:** AUROBINDO PHARMA,  
 MEYERSDAL, JOHANNESBURG  
**Shelf-life:** 24 months (Provisional)  
**Date of registration:** 23 JULY 2010

**MRF15**

**Registration number:** 41/3.1/0469  
**Name of medicine:** FLAMARYX 7,5 mg  
**Dosage form:** TABLET  
**Active ingredients:** EACH TABLET CONTAINS:  
 MELOXICAM 7,5 mg  
**Conditions of registration:** 1, 2, 3, 4, 5, 6, 7, 8  
**Applicant:** AUROBINDO PHARMA (PTY) LTD  
**Manufacturer:** AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
**Packer:** AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
**Laboratory: FPRC:** AUROBINDO PHARMA LTD,  
 UNIT III, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
**FPRR:** AUROBINDO PHARMA,  
 MEYERSDAL,  
 JOHANNESBURG  
**Shelf-life:** 24 months (Provisional)  
**Date of registration:** 23 JULY 2010

**MRF 15**

**Registration number:** 41/3.1/0470  
**Name of medicine:** FLAMARYX 15 mg  
**Dosage form:** TABLET  
**Active ingredients:** EACH TABLET CONTAINS:  
 MELOXICAM 15,0 mg  
**Conditions of registration:** 1, 2, 3, 4, 5, 6, 7, 8  
**Applicant:** AUROBINDO PHARMA (PTY) LTD  
**Manufacturer:** AUROBINDO PHARMA LTD, UNIT III,  
 QUTHUBULLAPUR MANDAL, RANGA  
 REDDY DISTRICT, ANDHRA  
 PRADESH, INDIA  
**Packer:** AUROBINDO PHARMA LTD, UNIT III,  
 QUTHUBULLAPUR MANDAL, RANGA  
 REDDY DISTRICT, ANDHRA  
 PRADESH, INDIA  
**Laboratory: FPRC:** AUROBINDO PHARMA LTD, UNIT III,  
 QUTHUBULLAPUR MANDAL, RANGA  
 REDDY DISTRICT, ANDHRA  
 PRADESH, INDIA  
**FPRR:** AUROBINDO PHARMA,  
 MEYERSDAL, JOHANNESBURG  
**Shelf-life:** 24 months (Provisional)  
**Date of registration:** 23 JULY 2010

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/20.2.8/0936  |
| Name of medicine:           | SONKE LAMIVUDINE + ZIDOVUDINE 150/300 AND SONKE EFAVIRENZ 600 CO-PACK   |
| Dosage form:                | TABLETS   |
| Active ingredients:         | EACH BLISTER CONTAINS:<br>2 x SONKE LAMIVUDINE + ZIDOVUDINE TABLETS CONTAINING<br>LAMIVUDINE 150,0 mg<br>ZIDOVUDINE 300,0 mg<br><br>1 x SONKE EFAVIRENZ 600 TABLET CONTAINING<br>EFAVIRENZ 600,0 mg                                       |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7   |
| Applicant:                  | RANBAXY (S.A.) (PTY) LTD  |
| Manufacturer:               | RANBAXY LABORATORIES LTD, PAONTA SAHIB, SIRMOUR, HIMACHAL PRADESH, INDIA  |
| Packer:                     | RANBAXY LABORATORIES LTD, PAONTA SAHIB, SIRMOUR, HIMACHAL PRADESH, INDIA  |
| Laboratory: FPRC:           | RANBAXY LABORATORIES LTD, PAONTA SAHIB, SIRMOUR, HIMACHAL PRADESH, INDIA<br>KHULULEKANI LABORATORY SERVICES, COVENTRY PARK, MIDRAND<br>CONSULTING CHEMICAL LABORATORIES, ATLASVILLE, BOKSBURG<br>BE-TABS PHARMACEUTICALS, ROODEPOORT, RSA |
| FPRR:                       | RANBAXY (S.A.), CENTURION, RSA  |
| Shelf-life:                 | 24 months   |
| Date of registration:       | 23 JULY 2010  |

## MRF15

|                             |  |
|-----------------------------|--|
| Registration number:        | 42/20.2.8/0973   |
| Name of medicine:           | RENZIR 50 mg   |
| Dosage form:                | CAPSULE  |
| Active ingredients:         | EACH CAPSULE CONTAINS:<br>EFAVIRENZ 50,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8   |
| Applicant:                  | ADCOCK INGRAM LIMITED  |
| Manufacturer:               | ADCOCK INGRAM HEALTHCARE, WADEVILLE, GERMISTON   |
| Packer:                     | ADCOCK INGRAM HEALTHCARE, WADEVILLE, GERMISTON   |
| Laboratory: FPRC/FPRR       | ADCOCK INGRAM HEALTHCARE, WADEVILLE, GERMISTON<br>ADCOCK INGRAM LTD, AEROTON, JOHANNESBURG |
| FPRR:                       | ADCOCK INGRAM LTD, ERAND GARDENS, MIDRAND  |
| Shelf-life:                 | 24 months (Provisional)  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 42/20.2.8/0974   |
| Name of medicine:           | RENZIR 100 mg  |
| Dosage form:                | CAPSULE  |
| Active ingredients:         | EACH CAPSULE CONTAINS:<br>EFAVIRENZ 100,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8   |
| Applicant:                  | ADCOCK INGRAM LIMITED  |
| Manufacturer:               | ADCOCK INGRAM HEALTHCARE, WADEVILLE, GERMISTON   |
| Packer:                     | ADCOCK INGRAM HEALTHCARE, WADEVILLE, GERMISTON   |
| Laboratory: FPRC/FPRR       | ADCOCK INGRAM HEALTHCARE, WADEVILLE, GERMISTON<br>ADCOCK INGRAM LTD, AEROTON, JOHANNESBURG |
| FPRR:                       | ADCOCK INGRAM LTD, ERAND GARDENS, MIDRAND  |
| Shelf-life:                 | 24 months (Provisional)  |
| Date of registration:       | 23 JULY 2010   |

**MRF 15**

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/20.2.8/0976  |
| Name of medicine:           | REFAVIN 50 mg   |
| Dosage form:                | CAPSULE   |
| Active ingredients:         | EACH CAPSULE CONTAINS:<br>EFAVIRENZ 50,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | ADCOCK INGRAM LIMITED   |
| Manufacturer:               | ADCOCK INGRAM<br>HEALTHCARE, WADEVILLE,<br>GERMISTON  |
| Packer:                     | ADCOCK INGRAM<br>HEALTHCARE, WADEVILLE,<br>GERMISTON  |
| Laboratory: FPRC/FPRR:      | ADCOCK INGRAM<br>HEALTHCARE, WADEVILLE,<br>GERMISTON<br>ADCOCK INGRAM LTD,<br>AEROTON, JOHANNESBURG |
| FPRR:                       | ADCOCK INGRAM LTD, ERAND<br>GARDENS, MIDRAND  |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

**MRF15**

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/20.2.8/0977  |
| Name of medicine:           | REFAVIN 100 mg  |
| Dosage form:                | CAPSULE   |
| Active ingredients:         | EACH CAPSULE CONTAINS:<br>EFAVIRENZ 100,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | ADCOCK INGRAM LIMITED   |
| Manufacturer:               | ADCOCK INGRAM<br>HEALTHCARE, WADEVILLE,<br>GERMISTON  |
| Packer:                     | ADCOCK INGRAM<br>HEALTHCARE, WADEVILLE,<br>GERMISTON  |
| Laboratory: FPRC/FPRR:      | ADCOCK INGRAM<br>HEALTHCARE, WADEVILLE,<br>GERMISTON<br>ADCOCK INGRAM LTD,<br>AEROTON, JOHANNESBURG |
| FPRR:                       | ADCOCK INGRAM LTD, ERAND<br>GARDENS, MIDRAND  |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

**MRF 15**

|                             |  |
|-----------------------------|--|
| Registration number:        | 42/20.2.8/0979   |
| Name of medicine:           | ADCO EFAVIRENZ 50 mg   |
| Dosage form:                | CAPSULE  |
| Active ingredients:         | EACH CAPSULE CONTAINS:<br>EFAVIRENZ 50,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8   |
| Applicant:                  | ADCOCK INGRAM LIMITED  |
| Manufacturer:               | ADCOCK INGRAM HEALTHCARE,<br>WADEVILLE, GERMISTON  |
| Packer:                     | ADCOCK INGRAM HEALTHCARE,<br>WADEVILLE, GERMISTON  |
| Laboratory: FPRC/FPRR:      | ADCOCK INGRAM HEALTHCARE,<br>WADEVILLE, GERMISTON<br>ADCOCK INGRAM LTD, AEROTON,<br>JOHANNESBURG |
| FPRR:                       | ADCOCK INGRAM LTD, ERAND<br>GARDENS, MIDRAND   |
| Shelf-life:                 | 24 months (Provisional)  |
| Date of registration:       | 23 JULY 2010   |

**MRF 15**

Registration number: 42/20.2.8/0980  
 Name of medicine: ADCO EFAVIRENZ 100 mg  
 Dosage form: CAPSULE  
 Active ingredients: EACH CAPSULE CONTAINS:  
 EFAVIRENZ 100,0 mg  
 Conditions of registration: 1, 2, 3, 4, 5, 6, 7, 8  
 Applicant: ADCOCK INGRAM LIMITED  
 Manufacturer: ADCOCK INGRAM  
 HEALTHCARE, WADEVILLE,  
 GERMISTON  
 Packer: ADCOCK INGRAM  
 HEALTHCARE, WADEVILLE,  
 GERMISTON  
 Laboratory: FPRC/FPRR: ADCOCK INGRAM  
 HEALTHCARE, WADEVILLE,  
 GERMISTON  
 ADCOCK INGRAM LTD,  
 AEROTON,  
 JOHANNESBURG  
 FPRR: ADCOCK INGRAM LTD,  
 ERAND GARDENS,  
 MIDRAND  
 Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

**MRF15**

Registration number: 42/21.2/1033  
 Name of medicine: GLIMY 1  
 Dosage form: TABLET  
 Active ingredients: EACH TABLET CONTAINS:  
 GLIMEPIRIDE 1,0 mg  
 Conditions of registration: 1, 2, 3, 4, 5, 6, 7, 8  
 Applicant: DR REDDY'S  
 LABORATORIES (PTY) LTD  
 Manufacturer: DR REDDY'S  
 LABORATORIES LTD,  
 QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA  
 PRADESH, INDIA  
 Packer: DR REDDY'S  
 LABORATORIES LTD,  
 QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA  
 PRADESH, INDIA  
 Laboratory: FPRC: DR REDDY'S  
 LABORATORIES LTD,  
 QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA  
 PRADESH, INDIA  
 RESEARCH INSTITUTE  
 FOR INDUSTRIAL  
 PHARMACY, NORTH-WEST  
 UNIVERSITY,  
 POTCHEFSTROOM  
 FPRR: DR REDDY'S  
 LABORATORIES,  
 MURRAYFIELD, PRETORIA  
 Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

**MRF 15**

Registration number: 42/21.2/1034  
 Name of medicine: GLIMY 2  
 Dosage form: TABLET  
 Active ingredients: EACH TABLET CONTAINS:  
 GLIMEPIRIDE 2,0 mg  
 Conditions of registration: 1, 2, 3, 4, 5, 6, 7, 8  
 Applicant: DR REDDY'S LABORATORIES  
 (PTY) LTD  
 Manufacturer: DR REDDY'S LABORATORIES  
 LTD, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
 Packer: DR REDDY'S LABORATORIES  
 LTD, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
 Laboratory: FPRC: DR REDDY'S LABORATORIES  
 LTD, QUTHUBULLAPUR  
 MANDAL, RANGA REDDY  
 DISTRICT, ANDHRA PRADESH,  
 INDIA  
 RESEARCH INSTITUTE FOR  
 INDUSTRIAL PHARMACY,  
 NORTH-WEST UNIVERSITY,  
 POTCHEFSTROOM  
 FPRR: DR REDDY'S LABORATORIES,  
 MURRAYFIELD, PRETORIA  
 Shelf-life: 24 months (Provisional)  
 Date of registration: 23 JULY 2010

**MRF 15**

|                             |   |
|-----------------------------|---|
| Registration number:        | 42/21.2/1035  |
| Name of medicine:           | GLIMY 4   |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>GLIMEPIRIDE 4,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | DR REDDY'S LABORATORIES<br>(PTY) LTD  |
| Manufacturer:               | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA  |
| Packer:                     | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA  |
| Laboratory: FPRC:           | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA<br>RESEARCH INSTITUTE FOR<br>INDUSTRIAL PHARMACY,<br>NORTH-WEST UNIVERSITY,<br>POTCHEFSTROOM |
| FPRR:                       | DR REDDY'S LABORATORIES,<br>MURRAYFIELD, PRETORIA   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

**MRF15**

|                             |   |
|-----------------------------|---|
| Registration number:        | 43/7.1.3/0032   |
| Name of medicine:           | MIGROBEN 80 TABLET  |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 80,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7   |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD  |
| Manufacturer:               | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARBERA DEL VALLES,<br>BARCELONA, SPAIN  |
| Packer:                     | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARBERA DEL VALLES,<br>BARCELONA, SPAIN<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG,<br>PRATTELN, SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARBERA DEL VALLES,<br>BARCELONA, SPAIN<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG   |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK   |
| Shelf-life:                 | 36 months   |
| Date of registration:       | 23 JULY 2010  |

**MRF 15**

|                             |   |
|-----------------------------|---|
| Registration number:        | 43/7.1.3/0033   |
| Name of medicine:           | MIGROBEN 160 TABLET   |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7   |
| Applicant:                  | NOVARTIS SOUTH AFRICA (PTY)<br>LTD  |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A.,<br>BARBERA DEL VALLES,<br>BARCELONA, SPAIN  |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A.,<br>BARBERA DEL VALLES,<br>BARCELONA, SPAIN<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC            | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A.,<br>BARBERA DEL VALLES,<br>BARCELONA, SPAIN<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG   |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK   |
| Shelf-life:                 | 36 months   |
| Date of registration:       | 23 JULY 2010  |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0034  |
| Name of medicine:           | RINTEZEX 80 TABLET   |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 80,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARERA DEL VALLES,<br>BARCELONA, SPAIN  |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARERA DEL VALLES,<br>BARCELONA, SPAIN<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory:                 | FPRC: NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARERA DEL VALLES,<br>BARCELONA, SPAIN<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG   |
|                             | FPRC/FPRR: NOVARTIS SA, SPARTAN,<br>KEMPTON PARK   |
| Shelf-life:                 | 36 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0035  |
| Name of medicine:           | RINTEZEX 160 TABLET  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARERA DEL VALLES,<br>BARCELONA, SPAIN  |
| Packer:                     | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARERA DEL VALLES,<br>BARCELONA, SPAIN<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG,<br>PRATTELN, SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>NOVARTIS SA, SPARTAN, |
| Laboratory:                 | FPRC: NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA<br>S.A., BARERA DEL VALLES,<br>BARCELONA, SPAIN<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG   |
|                             | FPRC/FPRR: NOVARTIS SA, SPARTAN,<br>KEMPTON PARK   |
| Shelf-life:                 | 36 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 43/7.1.3/0036   |
| Name of medicine:           | ZOMEVEK 80 TABLET   |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 80,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7   |
| Applicant:                  | NOVARTIS SOUTH AFRICA (PTY)<br>LTD  |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A.,<br>BARERA DEL VALLES, BARCELONA,<br>SPAIN   |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A.,<br>BARERA DEL VALLES, BARCELONA,<br>SPAIN<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>NOVARTIS SA, SPARTAN |
| Laboratory:                 | FPRC: NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A.,<br>BARERA DEL VALLES, BARCELONA,<br>SPAIN<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
|                             | FPRC/FPRR: NOVARTIS SA, SPARTAN,<br>KEMPTON PARK  |
| Shelf-life:                 | 36 months   |
| Date of registration:       | 23 JULY 2010  |

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 43/7.1.3/0037   |
| Name of medicine:           | ZOMEVEK 160 TABLET  |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7   |
| Applicant:                  | NOVARTIS SOUTH AFRICA (PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A., BARBERA DEL VALLES, BARCELONA, SPAIN   |
| Packer:                     | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A., BARBERA DEL VALLES, BARCELONA, SPAIN<br>ALLPACK AG, REINACH, SWITZERLAND<br>KONAPHARMA AG, PRATTELN, SWITZERLAND<br>NOVARTIS PHARMA GmbH, WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF, SWITZERLAND<br>NOVARTIS SA, SPARTAN, KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS PHARMACEUTICA S.A., BARBERA DEL VALLES, BARCELONA, SPAIN<br>IVERS-LEE AG, BURGDORF, SWITZERLAND<br>M&L LABORATORY SERVICES, ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN, KEMPTON PARK  |
| Shelf-life:                 | 36 months   |
| Date of registration:       | 23 JULY 2010  |

## MRF15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0080  |
| Name of medicine:           | CO-ZOMEVEK 80/12,5 TABLET  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 80,0 mg<br>HYDROCHLOROTHIAZIDE 12,5 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA (PTY) LTD  |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH, SWITZERLAND<br>KONAPHARMA AG, PRATTELN, SWITZERLAND<br>NOVARTIS PHARMA GmbH, WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF, SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN, KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH, WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES, ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN, KEMPTON PARK   |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0081  |
| Name of medicine:           | CO-ZOMEVEK 160/12,5 TABLET   |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg<br>HYDROCHLOROTHIAZIDE 12,5 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA (PTY) LTD  |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH, SWITZERLAND<br>KONAPHARMA AG, PRATTELN, SWITZERLAND<br>NOVARTIS PHARMA GmbH, WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF, SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN, KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH, WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES, ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN, KEMPTON PARK   |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0082  |
| Name of medicine:           | CO-ZOMEVEK 160/25 TABLET   |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg<br>HYDROCHLOROTHIAZIDE<br>25,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN<br>PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK  |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0083  |
| Name of medicine:           | CO-MIGROBEN 80/12,5<br>TABLET  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 80,0 mg<br>HYDROCHLOROTHIAZIDE<br>12,5 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG,<br>PRATTELN, SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN<br>PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK  |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0084  |
| Name of medicine:           | CO-MIGROBEN 160/12,5 TABLET  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg<br>HYDROCHLOROTHIAZIDE<br>12,5 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA (PTY)<br>LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE<br>ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE<br>ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN<br>PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE<br>ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK  |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |



## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0085  |
| Name of medicine:           | CO-MIGROBEN 160/25 TABLET  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg<br>HYDROCHLOROTHIAZIDE<br>25,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN<br>PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK  |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0087  |
| Name of medicine:           | RINTEZEX CO 80/12,5 TABLET   |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 80,0 mg<br>HYDROCHLOROTHIAZIDE<br>12,5 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG,<br>PRATTELN, SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN<br>PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN<br>AG, STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK  |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0088  |
| Name of medicine:           | RINTEZEX CO 160/12,5 TABLET  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg<br>HYDROCHLOROTHIAZIDE<br>12,5 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA (PTY)<br>LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE<br>ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE<br>ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN<br>PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory: FPRC:           | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A., TORRE<br>ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
| FPRC/FPRR:                  | NOVARTIS SA, SPARTAN,<br>KEMPTON PARK  |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/7.1.3/0089  |
| Name of medicine:           | RINTEZEX CO 160/25 TABLET  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>VALSARTAN 160,0 mg<br>HYDROCHLOROTHIAZIDE<br>25,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | NOVARTIS SOUTH AFRICA<br>(PTY) LTD   |
| Manufacturer:               | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY   |
| Packer:                     | NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>ALLPACK AG, REINACH,<br>SWITZERLAND<br>KONAPHARMA AG, PRATTELN,<br>SWITZERLAND<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>IVERS-LEE AG, BURGDORF,<br>SWITZERLAND<br>LAMP S. PROSPERO SpA, SAN<br>PROSPERO, MODENA, ITALY<br>MIPHARM SpA, MILAN, ITALY<br>NOVARTIS SA, SPARTAN,<br>KEMPTON PARK |
| Laboratory:                 | FPRC: NOVARTIS PHARMA STEIN AG,<br>STEIN, SWITZERLAND<br>NOVARTIS FARMA S.p.A.,<br>TORRE ANNUNZIATA, ITALY<br>NOVARTIS PHARMA GmbH,<br>WEHR/BADEN, GERMANY<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG  |
|                             | FPRC/FPRR: NOVARTIS SA, SPARTAN,<br>KEMPTON PARK   |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF15

|                             |   |
|-----------------------------|---|
| Registration number:        | 43/21.2/0605  |
| Name of medicine:           | DRL GLIMEPIRIDE 1   |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>GLIMEPIRIDE 1,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | DR REDDY'S LABORATORIES<br>(PTY) LTD  |
| Manufacturer:               | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA  |
| Packer:                     | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA<br>DRA PHARMACEUTICALS,<br>IRENE, CENTURION<br>TECHNIKON LABORATORIES,<br>ROBERTVILLE, FLORIDA<br>DIVPHARM MANUFACTURING<br>& PACKAGING, LONGDALE,<br>JOHANNESBURG |
| Laboratory:                 | FPRC: DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA<br>RESEARCH INSTITUTE FOR<br>INDUSTRIAL PHARMACY,<br>NORTH-WEST UNIVERSITY,<br>POTCHEFSTROOM   |
|                             | FPRR: DR REDDY'S LABORATORIES,<br>MURRAYFIELD, PRETORIA   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 43/21.2/0608   |
| Name of medicine:           | DRL GLIMEPIRIDE 2  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>GLIMEPIRIDE 2,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8   |
| Applicant:                  | DR REDDY'S LABORATORIES (PTY)<br>LTD   |
| Manufacturer:               | DR REDDY'S LABORATORIES LTD,<br>QUTHUBULLAPUR MANDAL, RANGA<br>REDDY DISTRICT, ANDHRA<br>PRADESH, INDIA  |
| Packer:                     | DR REDDY'S LABORATORIES LTD,<br>QUTHUBULLAPUR MANDAL, RANGA<br>REDDY DISTRICT, ANDHRA<br>PRADESH, INDIA<br>DRA PHARMACEUTICALS, IRENE,<br>CENTURION<br>TECHNIKON LABORATORIES,<br>ROBERTVILLE, FLORIDA<br>DIVPHARM MANUFACTURING &<br>PACKAGING, LONGDALE,<br>JOHANNESBURG |
| Laboratory:                 | FPRC:: DR REDDY'S LABORATORIES LTD,<br>QUTHUBULLAPUR MANDAL, RANGA<br>REDDY DISTRICT, ANDHRA<br>PRADESH, INDIA<br>RESEARCH INSTITUTE FOR<br>INDUSTRIAL PHARMACY, NORTH-<br>WEST UNIVERSITY,<br>POTCHEFSTROOM   |
|                             | FPRR: DR REDDY'S LABORATORIES,<br>MURRAYFIELD, PRETORIA  |
| Shelf-life:                 | 24 months (Provisional)  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

|                             |   |
|-----------------------------|---|
| Registration number:        | 43/21.2/0607  |
| Name of medicine:           | DRL GLIMEPIRIDE 4   |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>GLIMEPIRIDE 4,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | DR REDDY'S LABORATORIES<br>(PTY) LTD  |
| Manufacturer:               | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA  |
| Packer:                     | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA<br>DRA PHARMACEUTICALS,<br>IRENE, CENTURION<br>TECHNIKON LABORATORIES,<br>ROBERTVILLE, FLORIDA<br>DIVPHARM MANUFACTURING &<br>PACKAGING, LONGDALE,<br>JOHANNESBURG |
| Laboratory: FPRC:           | DR REDDY'S LABORATORIES<br>LTD, QUTHUBULLAPUR<br>MANDAL, RANGA REDDY<br>DISTRICT, ANDHRA PRADESH,<br>INDIA<br>RESEARCH INSTITUTE FOR<br>INDUSTRIAL PHARMACY,<br>NORTH-WEST UNIVERSITY,<br>POTCHEFSTROOM   |
| FPRR:                       | DR REDDY'S LABORATORIES,<br>MURRAYFIELD, PRETORIA   |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF15

|                             |   |
|-----------------------------|---|
| Registration number:        | 43/20.2.8/0832  |
| Name of medicine:           | ASPEN LAMIVUDINE 300 mg   |
| Dosage form:                | TABLET  |
| Active ingredients:         | EACH TABLET CONTAINS:<br>LAMIVUDINE 300,0 mg  |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7, 8  |
| Applicant:                  | PHARMACARE LIMITED  |
| Manufacturer:               | STRIDES ARCOLAB LTD,<br>ANEKAL TALUK, BANGALORE,<br>INDIA<br>ASPED OSD, GIBAUD ROAD,<br>PORT ELIZABETH  |
| Packer:                     | STRIDES ARCOLAB LTD,<br>ANEKAL TALUK, BANGALORE,<br>INDIA<br>ASPED OSD, GIBAUD ROAD,<br>PORT ELIZABETH  |
| Laboratory: FPRC:           | STRIDES ARCOLAB LTD,<br>ANEKAL TALUK, BANGALORE,<br>INDIA<br>M&L LABORATORY SERVICES,<br>ORMONDE, JOHANNESBURG<br>RESEARCH INSTITUTE FOR<br>INDUSTRIAL PHARMACY,<br>NORTH-WEST UNIVERSITY,<br>POTCHEFSTROOM<br>SABS PHARMACEUTICAL<br>CHEMISTRY LABORATORY,<br>GROENKLOOF, PRETORIA |
| FPRC/FPRR:                  | ASPEN OSD, GIBAUD ROAD,<br>PORT ELIZABETH   |
| FPRR:                       | PHARMACARE LTD,<br>WOODMEAD, SANDTON  |
| Shelf-life:                 | 24 months (Provisional)   |
| Date of registration:       | 23 JULY 2010  |

## MRF 15

|                             |  |
|-----------------------------|--|
| Registration number:        | 44/20.2.8/0294   |
| Name of medicine:           | ADCO LAMIVUDINE 300 mg<br>TABLETS  |
| Dosage form:                | TABLET   |
| Active ingredients:         | EACH TABLET CONTAINS:<br>LAMIVUDINE 300,0 mg   |
| Conditions of registration: | 1, 2, 3, 4, 5, 6, 7  |
| Applicant:                  | ADCOCK INGRAM LIMITED  |
| Manufacturer:               | HETERO DRUGS, JEEDIMETLA,<br>HYDERABAD, INDIA<br>ADCOCK INGRAM HEALTHCARE,<br>WADEVILLE, GERMISTON |
| Packer:                     | HETERO DRUGS, JEEDIMETLA,<br>HYDERABAD, INDIA<br>ADCOCK INGRAM HEALTHCARE,<br>WADEVILLE, GERMISTON |
| Laboratory: FPRC:           | HETERO DRUGS, JEEDIMETLA,<br>HYDERABAD, INDIA  |
| FPRC/FPRR:                  | ADCOCK INGRAM HEALTHCARE,<br>WADEVILLE, GERMISTON<br>ADCOCK INGRAM LTD, AERDTON,<br>JOHANNESBURG   |
| FPRR:                       | ADCOCK INGRAM LTD, ERAND<br>GARDENS, MIDRAND   |
| Shelf-life:                 | 24 months  |
| Date of registration:       | 23 JULY 2010   |

## MRF 15

Registration number: 44/20.2.8/0295  
 Name of medicine: RETLAM 300 mg TABLETS  
 Dosage form: TABLET  
 Active ingredients: EACH TABLET CONTAINS:  
 LAMIVUDINE 300,0 mg

Conditions of registration: 1, 2, 3, 4, 5, 6, 7

Applicant: ADCOCK INGRAM LIMITED

Manufacturer: HETERO DRUGS, JEEDIMETLA,  
 HYDERABAD, INDIA  
 ADCOCK INGRAM HEALTHCARE,  
 WADEVILLE, GERMISTON

Packer: HETERO DRUGS, JEEDIMETLA,  
 HYDERABAD, INDIA  
 ADCOCK INGRAM HEALTHCARE,  
 WADEVILLE, GERMISTON

Laboratory: FPRC: HETERO DRUGS, JEEDIMETLA,

## MRF15

Registration number: 44/20.2.8/0296  
 Name of medicine: LAVOS 300 mg TABLETS  
 Dosage form: TABLET  
 Active ingredients: EACH TABLET CONTAINS:  
 LAMIVUDINE 300,0 mg

Conditions of registration: 1, 2, 3, 4, 5, 6, 7

Applicant: ADCOCK INGRAM LIMITED

Manufacturer: HETERO DRUGS, JEEDIMETLA,  
 HYDERABAD, INDIA  
 ADCOCK INGRAM HEALTHCARE,  
 WADEVILLE, GERMISTON

Packer: HETERO DRUGS, JEEDIMETLA,  
 HYDERABAD, INDIA  
 ADCOCK INGRAM HEALTHCARE,  
 WADEVILLE, GERMISTON

Laboratory: FPRC: HETERO DRUGS, JEEDIMETLA,

## MRF 15

Registration number: 44/20.1/0897  
 Name of medicine: AREPANDRIX H1N1  
 Dosage form: INJECTION  
 Active ingredients: EACH 0,5 ml DOSE CONTAINS:  
 SPLIT INFLUENZA VIRUS  
 A/CALIFORNIA/7/2009(H1N1)  
 V-LIKE VIRUS 3,75 µg

Conditions of registration: 1, 2, 3, 4, 5, 6, 7

Applicant: GLAXOSMITHKLINE S.A. (PTY) LTD

Manufacturer: GLAXOSMITHKLINE BIOLOGICALS NORTH  
 AMERICA, SAINTE-FOY, QUEBEC,  
 CANADA  
 GLAXOSMITHKLINE BIOLOGICALS  
 MANUFACTURING SA, RIXENSART,  
 BELGIUM  
 GLAXOSMITHKLINE BIOLOGICALS  
 MANUFACTURING SA, WAVRE, BELGIUM  
 GLAXOSMITHKLINE BIOLOGICALS, SAINT  
 AMAND LES EAUX, FRANCE  
 GLAXOSMITHKLINE BIOLOGICALS NORTH  
 AMERICA, MARIETTA, PA, USA  
 GLAXO WELCOME OPERATIONS UK,  
 BARNARD CASTLE, DURHAM, UK  
 VETTER PHARMA INTERNATIONAL GmbH,  
 MOOSWIESEN, RAVENSBURG, GERMANY  
 DSM, GREENVILLE, NC, USA  
 BAXTER PHARMACEUTICAL SOLUTIONS,  
 BLOOMINGTON, INDIANA, USA  
 HOSPIRA INC, MCPHERSON, KANSAS,  
 USA

Packer: GLAXOSMITHKLINE BIOLOGICALS NORTH  
 AMERICA, SAINTE-FOY, QUEBEC,  
 CANADA  
 GLAXOSMITHKLINE BIOLOGICALS  
 MANUFACTURING SA, RIXENSART,  
 BELGIUM  
 GLAXOSMITHKLINE BIOLOGICALS  
 MANUFACTURING SA, WAVRE, BELGIUM  
 GLAXOSMITHKLINE BIOLOGICALS NORTH  
 AMERICA, MARIETTA, PA, USA  
 GLAXO WELCOME OPERATIONS UK,  
 BARNARD CASTLE, DURHAM, UK  
 VETTER PHAMRA INTERNATIONAL GmbH,  
 MOOSWIESEN, RAVENSBURG, GERMANY  
 HOLLISTER-STIER LABORATORIES,  
 SPOKANE, WA, USA  
 DSM, GREENVILLE, NC, USA  
 PIERRE FABRE MEDICAMENT  
 PRODUCTION, CHATEAURENARD,  
 FRANCE  
 PIERRE FABRE MEDICAMENT  
 PRODUCTION, CHEMIN DE MAZEROLLES,  
 IDRON, FRANCE  
 PIERRE FABRE MEDICAMENT  
 PRODUCTION, IDRON FRANCE  
 BAXTER PHARMACEUTICAL SOLUTIONS,  
 BLOOMINGTON, INDIANA, USA  
 HOSPIRA INC, MCPHERSON, KANSAS,  
 USA  
 GLAXOSMITHKLINE S.A., EPPING, CAPE  
 TOWN

Laboratory: FPRC: GLAXOSMITHKLINE BIOLOGICALS NORTH

HYDERABAD, INDIA

FPRC/FPRR: ADCKOCK INGRAM HEALTHCARE,  
WADEVILLE, GERMISTON  
ADCKOCK INGRAM LTD, AEROTON,  
JOHANNESBURG

FPRR: ADCKOCK INGRAM LTD, ERAND  
GARDENS, MIDRAND

Shelf-life: 24 months

Date of registration: 23 JULY 2010

HYDERABAD, INDIA

FPRC/FPRR: ADCKOCK INGRAM HEALTHCARE,  
WADEVILLE, GERMISTON  
ADCKOCK INGRAM LTD, AEROTON,  
JOHANNESBURG

FPRR: ADCKOCK INGRAM LTD, ERAND  
GARDENS, MIDRAND

Shelf-life: 24 months

Date of registration: 23 JULY 2010

AMERICA, SAINTE-FOY, QUEBEC,  
CANADA  
GLAXOSMITHKLINE BIOLOGICALS  
MANUFACTURING SA, RIXENSART,  
BELGIUM  
GLAXOSMITHKLINE BIOLOGICALS  
MANUFACTURING SA, WAVRE, BELGIUM  
GLAXOSMITHKLINE BIOLOGICALS, SAINT  
AMAND LES EAUX, FRANCE  
GLAXOSMITHKLINE BIOLOGICALS NORTH  
AMERICA, MARIETTA, PA, USA  
GLAXO WELCOME OPERATIONS UK,  
BARNARD CASTLE, DURHAM, UK  
VETTER PHARMA INTERNATIONAL GmbH,  
MOOSWIESEN, RAVENSBURG, GERMANY  
HOLLISTER-STIER LABORATORIES,  
SPOKANE, WA, USA  
DSM, GREENVILLE, NC, USA  
PIERRE FABRE MEDICAMENT  
PRODUCTION, CHATEAURENARD,  
FRANCE  
PIERRE FABRE MEDICAMENT  
PRODUCTION, CHEMIN DE MAZEROLLES,  
IDRON, FRANCE  
PIERRE FABRE MEDICAMENT  
PRODUCTION, IDRON FRANCE  
BAXTER PHARMACEUTICAL SOLUTIONS,  
BLOOMINGTON, INDIANA, USA  
HOSPIRA INC, MCPHERSON, KANSAS,  
USA

FPRC/FPRR: GLAXOSMITHKLINE S.A., EPPING, CAPE  
TOWN

Shelf-life: 24 months

Date of registration: 23 JULY 2010



Printed by and obtainable from the Government Printer, Bosman Street, Private Bag X85, Pretoria, 0001  
Publications: Tel: (012) 334-4508, 334-4509, 334-4510  
Advertisements: Tel: (012) 334-4673, 334-4674, 334-4504  
Subscriptions: Tel: (012) 334-4735, 334-4736, 334-4737  
Cape Town Branch: Tel: (021) 465-7531

Gedruk deur en verkrygbaar by die Staatsdrukker, Bosmanstraat, Privaatsak X85, Pretoria, 0001  
Publikasies: Tel: (012) 334-4508, 334-4509, 334-4510  
Advertensies: Tel: (012) 334-4673, 334-4674, 334-4504  
Subskripsies: Tel: (012) 334-4735, 334-4736, 334-4737  
Kaapstad-tak: Tel: (021) 465-7531